Madhu Kumar
Stock Analyst at Goldman Sachs
(2.87)
# 1,640
Out of 4,837 analysts
153
Total ratings
55.45%
Success rate
18.82%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Initiates: Buy | $169 | $111.02 | +52.22% | 7 | Jun 5, 2024 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $6.52 | -7.90% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $19.24 | +35.14% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $12.74 | +33.44% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $1.37 | +191.97% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $131.60 | +17.78% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $32.66 | +62.28% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $3.68 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $16.29 | +348.13% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $18.51 | +661.75% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $10.57 | +221.67% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $1.91 | +214.14% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $12.70 | +10.24% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $10.42 | +101.54% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $14.87 | -66.38% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $1.64 | +387.80% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $6.64 | +1,240.36% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $6 | $0.31 | +1,809.61% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.44 | +2,196.21% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $9.67 | +779.01% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $1.54 | +2,432.47% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $15.31 | +272.31% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.21 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.75 | +51,328.57% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $4.73 | +322.83% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $1.30 | +7,594.68% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $31.54 | +10.97% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.38 | +15,681.17% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $6.21 | +544.12% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $14.47 | +3,383.07% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $291.74 | -21.16% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $60 | $7.95 | +654.72% | 5 | Jul 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.77 | +2,159.89% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $35.47 | -39.39% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $39.25 | -40.13% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Jun 5, 2024
Initiates: Buy
Price Target: $169
Current: $111.02
Upside: +52.22%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $6.52
Upside: -7.90%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $19.24
Upside: +35.14%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $12.74
Upside: +33.44%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $1.37
Upside: +191.97%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $131.60
Upside: +17.78%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $32.66
Upside: +62.28%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.68
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $16.29
Upside: +348.13%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $18.51
Upside: +661.75%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $10.57
Upside: +221.67%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $1.91
Upside: +214.14%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $12.70
Upside: +10.24%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $10.42
Upside: +101.54%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $14.87
Upside: -66.38%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $1.64
Upside: +387.80%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $6.64
Upside: +1,240.36%
Jan 19, 2022
Downgrades: Neutral
Price Target: $29 → $6
Current: $0.31
Upside: +1,809.61%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.44
Upside: +2,196.21%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $9.67
Upside: +779.01%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $1.54
Upside: +2,432.47%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $15.31
Upside: +272.31%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $3.21
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.75
Upside: +51,328.57%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $4.73
Upside: +322.83%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $1.30
Upside: +7,594.68%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $31.54
Upside: +10.97%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.38
Upside: +15,681.17%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $6.21
Upside: +544.12%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $14.47
Upside: +3,383.07%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $291.74
Upside: -21.16%
Jul 6, 2018
Maintains: Neutral
Price Target: $120 → $60
Current: $7.95
Upside: +654.72%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.77
Upside: +2,159.89%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $35.47
Upside: -39.39%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $39.25
Upside: -40.13%